Cibc Asset Management Inc Bristol Myers Squibb CO Transaction History

Cibc Asset Management Inc

$25.9 Billion
Q2 2024

A detailed history of Cibc Asset Management Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Cibc Asset Management Inc holds 337,962 shares of BMY stock, worth $18 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

337,962

Previous 404,035 16.35%

Holding current value

$18 Million

Previous $21.9 Million 35.94%

% of portfolio

0.05%

Previous 0.08%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$40.25 - $52.99 $2.66 Million - $3.5 Million	-66,073 Reduced 16.35%	337,962 $14 Million
Q1 2024 May 09, 2024	BUY	$47.98 - $54.4 $2.58 Million - $2.93 Million	53,773 Added 15.35%	404,035 $21.9 Million
Q4 2023 Feb 13, 2024	SELL	$48.48 - $57.85 $1.01 Million - $1.2 Million	-20,737 Reduced 5.59%	350,262 $18 Million
Q3 2023 Oct 30, 2023	SELL	$57.89 - $64.73 $602,113 - $673,256	-10,401 Reduced 2.73%	370,999 $21.5 Million
Q2 2023 Aug 14, 2023	SELL	$63.71 - $70.74 $359,196 - $398,832	-5,638 Reduced 1.46%	381,400 $24.4 Million
Q1 2023 May 12, 2023	BUY	$65.71 - $74.53 $190,624 - $216,211	2,901 Added 0.76%	387,038 $26.8 Million
Q4 2022 Feb 13, 2023	SELL	$68.48 - $81.09 $7.16 Million - $8.48 Million	-104,542 Reduced 21.39%	384,137 $27.6 Million
Q3 2022 Nov 03, 2022	BUY	$0.13 - $76.84 $7,524 - $4.45 Million	57,883 Added 13.44%	488,679 $34.7 Million
Q2 2022 Aug 09, 2022	BUY	$72.62 - $79.98 $1.16 Million - $1.28 Million	15,959 Added 3.85%	430,796 $33.2 Million
Q1 2022 May 06, 2022	BUY	$61.48 - $73.72 $2.35 Million - $2.81 Million	38,156 Added 10.13%	414,837 $30.3 Million
Q4 2021 Feb 08, 2022	BUY	$53.63 - $62.52 $1.78 Million - $2.07 Million	33,186 Added 9.66%	376,681 $23.5 Million
Q3 2021 Nov 09, 2021	BUY	$59.17 - $69.31 $304,311 - $356,461	5,143 Added 1.52%	343,495 $20.3 Million
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $15,663 - $17,057	253 Added 0.07%	338,352 $22.6 Million
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $3.6 Million - $4.05 Million	-60,743 Reduced 15.23%	338,099 $21.3 Million
Q4 2020 Feb 03, 2021	BUY	$57.74 - $65.43 $1.26 Million - $1.42 Million	21,772 Added 5.77%	398,842 $24.7 Million
Q3 2020 Nov 05, 2020	BUY	$57.43 - $63.64 $1.03 Million - $1.14 Million	17,883 Added 4.98%	377,070 $22.7 Million
Q2 2020 Jul 28, 2020	BUY	$54.82 - $64.09 $7.75 Million - $9.05 Million	141,281 Added 64.84%	359,187 $21.1 Million
Q1 2020 Apr 30, 2020	SELL	$46.4 - $67.43 $127,182 - $184,825	-2,741 Reduced 1.24%	217,906 $12.1 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $3.27 Million - $4.27 Million	66,526 Added 43.16%	220,647 $14.2 Million
Q3 2019 Oct 30, 2019	BUY	$42.77 - $50.71 $304,180 - $360,649	7,112 Added 4.84%	154,121 $7.82 Million
Q2 2019 Aug 05, 2019	BUY	$44.62 - $49.34 $6,202 - $6,858	139 Added 0.09%	147,009 $6.67 Million
Q1 2019 May 06, 2019	SELL	$45.12 - $53.8 $71,334 - $85,057	-1,581 Reduced 1.06%	146,870 $7.01 Million
Q4 2018 Feb 12, 2019	SELL	$48.76 - $63.23 $105,857 - $137,272	-2,171 Reduced 1.44%	148,451 $7.72 Million
Q3 2018 Nov 02, 2018	SELL	$55.19 - $62.25 $68,270 - $77,003	-1,237 Reduced 0.81%	150,622 $9.35 Million
Q2 2018 Aug 09, 2018	BUY	$50.53 - $62.98 $278,218 - $346,767	5,506 Added 3.76%	151,859 $8.4 Million
Q1 2018 Apr 30, 2018	SELL	$59.92 - $68.98 $469,832 - $540,872	-7,841 Reduced 5.09%	146,353 $9.26 Million
Q4 2017 Feb 02, 2018	BUY	$59.94 - $65.35 $140,379 - $153,049	2,342 Added 1.54%	154,194 $9.45 Million
Q3 2017 Nov 06, 2017	BUY	$55.23 - $63.74 $8.39 Million - $9.68 Million	151,852	151,852 $9.68 Million

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Asset Management Inc with notifications on news.

Account

Cibc Asset Management Inc Bristol Myers Squibb CO Transaction History